
Vir Biotechnology Begins Phase 3 ECLIPSE Trial for Chronic Hepatitis Delta
Vir Biotechnology Launches Phase 3 ECLIPSE Program for Chronic Hepatitis Delta Treatment Vir Biotechnology, Inc. has officially enrolled its first patient in the Phase 3 ECLIPSE registrational program, a significant step in evaluating the efficacy and safety of the combination…